PTCT - Company ID 0001070081
PTC THERAPEUTICS, INC. trades as PTCT and has a market capitalization of $6.03 B, making it the #1285 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.73B, up 114.5% from the prior year and net income of $683.00M. This page tracks PTC THERAPEUTICS, INC. through 1,258 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-05-29
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years PTC THERAPEUTICS, INC.'s revenue grew from $82.70M to $1.73B, a compound annual growth rate of 40.2%. Net profit margin expanded from -171.8% to 39.5% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-19 |
| Insider sale notice | 144 | 2026-05-15 |
| Insider trade | 4 | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-14 |
| Insider sale notice | 144 | 2026-05-14 |
| Insider trade | 4 | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-08 |
| Quarterly report | 10-Q | 2026-05-07 |
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results | PTC Therapeutics.
PTC Therapeutics to Participate in Upcoming Investor Conferences | PTC Therapeutics.
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam | PTC Therapeutics.
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study | PTC Therapeutics.
Aromatic l-amino acid decarboxylase (AADC) deficiency
The largest companies sharing PTC THERAPEUTICS, INC.'s SEC industry classification (pharmaceutical preparations).
PTC THERAPEUTICS, INC. (PTCT) has a market capitalization of $6.03 B as of 2026-05-29, ranking #1285 among US-listed companies.
PTC THERAPEUTICS, INC. reported revenue of $1.73B for fiscal year 2025, an increase of 114.5% year over year.
Yes. PTC THERAPEUTICS, INC. reported net income of $683.00M in its latest fiscal year.